Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 300

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients

Open access
Schneider, Lynda C., Rachid, Rima, LeBovidge, Jennifer, Blood, Emily, Mittal, Mudita, Umetsu, Dale T.·2013·Journal of Allergy and Clinical Immunology
DOI 10.1016/j.jaci.2013.09.046
Open this paper in CoChat — free account

Abstract

Background Peanut allergy is a major public health problem that affects 1% of the population and has no effective therapy. Objective To examine the safety and efficacy of oraldesensitization in peanut allergic children in combination with a brief course of anti-IgE monoclonal antibody (omalizumab, Xolair). Methods We performed oral peanut desensitization in peanut allergic children at high risk for developing significant peanut-induced allergic reactions. Omalizumab was administered prior to and during oral peanut desensitization. Results We enrolled 13 children (median age, 10 years), with a median peanut-specific IgE of 229 kUA/L and a median total serum IgE of 621 kU/L, who failed an initial double-blind placebo controlled food challenge at doses 100 mg peanut flour. After pre-treatment with omalizumab, all subjects tolerated the initial 11 desensitization doses given on the first day, including the maximum dose of 500 mg peanut flour (cumulative dose, 992 mg, equivalent to >2 peanuts), requiring minimal or no rescue therapy. 12 subjects then reached the maximum maintenance dose of 4,000 mg peanut flour/day in a median time of 8 weeks, at which point omalizumab was discontinued. All 12 subjects continued on 4,000 mg peanut flour/day and subsequently tolerated a challenge with 8,000 mg peanut flour (equivalent to about 20 peanuts), or 160 to 400 times the dose tolerated before desensitization. During the study, 6 of the 13 subjects experienced mild or no allergic reactions; 6 subjects had Grade 2, and 2 subjects Grade 3 reactions, all of which responded rapidly to treatment. Conclusions Among children with high-risk peanut allergy, treatment with omalizumab may facilitate rapid oral desensitization, and qualitativelyimprove the desensitization process.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jaci.2013.09.046

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 37 references

Cited by

See all 300

Metadata

Authors
Schneider, L. C., Rachid, R., LeBovidge, J., Blood, E., Mittal, M., & Umetsu, D. T.
Venue
Journal of Allergy and Clinical Immunology
Publisher
Elsevier BV
Published
2013-12
Volume
132
Issue
6
Pages
1368-1374
ISSN
0091-6749 (ISSN-L)
DOI
10.1016/j.jaci.2013.09.046
OpenAlex
W2117748999
Cited by
300
References
37
FWCI
27.83
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients. https://app.cochat.ai/papers/10.1016/j.jaci.2013.09.046
The paper
Schneider, L. C., Rachid, R., LeBovidge, J., Blood, E., Mittal, M., & Umetsu, D. T. (2013). A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients. Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2013.09.046

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.